OTC Benzocaine Needs Label Warning, Indication Change – Public Citizen
This article was originally published in The Tan Sheet
In a citizen petition the group asks FDA to remove teething for children 2 years and older as an indication for some benzocaine products and require a label warning for OTC monograph benzocaine products concerning the risk of methemoglobinemia.
You may also be interested in...
In Brief: CHPA Disagrees With FDA Warning; Adulterated Supplements Enforcement; DASCA Support Sought
FDA warns about painkillers for teething; enforcement against adulterated supplements; FDA warning letter for tainted bee pollen; Akorn must divest brands from Hi-Tech deal; senators seek support for DASCA; and consumer acetaminophen knowledge improves.
Nearly two-thirds of FDA’s planned regulatory actions for the consumer health segment would update the OTC drug monograph, including changes to pediatric cough/cold labeling, acetaminophen dosing, oral care products with benzocaine and labeling for some laxatives.
Concern that products with the painkiller benzocaine are linked to rare but serious and potentially fatal adverse events prompted an FDA consumer warning and could lead to label and package changes.